About Viewray (NASDAQ:VRAY)
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210
Debt
Debt-to-Equity Ratio22.47%
Current Ratio2.18%
Quick Ratio1.84%
Price-To-Earnings
Trailing P/E Ratio-7.42
Forward P/E Ratio-10.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$34.04 million
Price / Sales15.93
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book252.00
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-72,170,000.00
Net Margins-212.02%
Return on EquityN/A
Return on Assets-60.04%
Miscellaneous
Employees139
Outstanding Shares71,740,000
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) released its quarterly earnings data on Monday, March, 12th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.13. The firm earned $19.90 million during the quarter, compared to analyst estimates of $21.23 million. The company's revenue was up 23.6% on a year-over-year basis. View Viewray's Earnings History.
What price target have analysts set for VRAY?
6 brokerages have issued 12 month price targets for Viewray's shares. Their forecasts range from $10.00 to $13.50. On average, they expect Viewray's stock price to reach $11.5833 in the next twelve months. View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018)
- 2. Northland Securities analysts commented, "We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly" intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size." (5/16/2017)
- 3. Aegis analysts commented, "We are assuming coverage of VRAY with a Buy rating and $11 PT. We believe the MRI-guided LINAC is a game-changer in radiation oncology, with real-time imaging improving dosimetry and reducing the toxicity to patients. The combination improves functionality and expands the use of stereotactic body radiation therapy (SBRT), and physicians believe the system can expand the total treatable tumors by at least 20%." (5/16/2017)
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include CONMED (CNMD), NxStage (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Rockwell Medical (RMTI), Vision Sciences (CGNT), Fonar (FONR), Helius Medical Technologies (HSDT), Zynex (ZYXI), Biolife Solutions (BLFS), Second Sight Medical (EYES), Viveve Medical (VIVE), Edap Tms (EDAP) and IRIDEX (IRIX).
When did Viewray IPO?
(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Has Viewray been receiving favorable news coverage?
Media coverage about VRAY stock has been trending somewhat positive on Wednesday, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viewray earned a daily sentiment score of 0.01 on Accern's scale. They also assigned media stories about the company an impact score of 45.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $7.56.
How big of a company is Viewray?
Viewray has a market capitalization of $553.86 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe.
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viewray (NASDAQ:VRAY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Viewray in the last 12 months. Their average twelve-month price target is $11.5833, suggesting that the stock has a possible upside of 53.22%. The high price target for VRAY is $13.50 and the low price target for VRAY is $10.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.5833 | $11.5833 | $11.20 | $10.00 |
| Price Target Upside: | 53.22% upside | 41.61% upside | 24.58% upside | 55.28% upside |
Viewray (NASDAQ:VRAY) Consensus Price Target History
Viewray (NASDAQ:VRAY) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Viewray (NASDAQ:VRAY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Viewray (NASDAQ VRAY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 62.81%
Institutional Ownership Percentage: 76.31%
Viewray (NASDAQ VRAY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/14/2018 | James F Dempsey | Insider | Sell | 75,243 | $7.57 | $569,589.51 | |  |
| 4/25/2017 | Fmr Llc | Insider | Sell | 106,781 | $6.76 | $721,839.56 | | |
| 4/24/2017 | Fmr Llc | Insider | Sell | 101,139 | $6.71 | $678,642.69 | | |
| 4/20/2017 | Fmr Llc | Insider | Sell | 101,236 | $6.90 | $698,528.40 | | |
| 4/18/2017 | Fmr Llc | Insider | Sell | 107,217 | $7.24 | $776,251.08 | | |
| 4/13/2017 | Fmr Llc | Insider | Sell | 115,860 | $7.44 | $861,998.40 | | |
| 4/12/2017 | Fmr Llc | Insider | Sell | 179,494 | $7.40 | $1,328,255.60 | | |
| 4/10/2017 | Fmr Llc | Insider | Sell | 178,556 | $7.77 | $1,387,380.12 | | |
| 4/7/2017 | Fmr Llc | Insider | Sell | 52,050 | $7.89 | $410,674.50 | | |
| 4/5/2017 | Fmr Llc | Insider | Sell | 196,397 | $7.90 | $1,551,536.30 | | |
| 4/3/2017 | Fmr Llc | Insider | Sell | 217,883 | $8.29 | $1,806,250.07 | | |
| 3/30/2017 | Fmr Llc | Insider | Sell | 28,661 | $8.46 | $242,472.06 | | |
| 1/18/2017 | Ajay Bansal | CFO | Buy | 62,597 | $3.17 | $198,432.49 | 70,104 | |
| 1/18/2017 | Henry A. Mckinnell | Director | Buy | 312,989 | $3.17 | $992,175.13 | | |
| 9/9/2016 | Aditya Puri | Director | Buy | 1,472,803 | $2.95 | $4,344,768.85 | 18,964 | |
| 8/22/2016 | David P Bonita | Director | Buy | 1,138,074 | $2.95 | $3,357,318.30 | | |
(Data available from 1/1/2013 forward)
Viewray (NASDAQ VRAY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $15.50 Million in Sales Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - April 25 at 4:52 AM |
| Zacks: Brokerages Anticipate Viewray Inc (VRAY) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 23 at 5:12 AM |
| Reviewing Viewray (VRAY) and Zynex (ZYXI)
www.americanbankingnews.com - April 22 at 7:26 AM |
 | VU University Medical Center in Amsterdam Delivers First Ever Linear Accelerator-Based On-Table Adaptive MR ...
www.prnewswire.com - April 19 at 5:57 PM |
| Viewray Target of Unusually Large Options Trading (VRAY)
www.americanbankingnews.com - April 19 at 8:00 AM |
| Viewray's (VRAY) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - April 19 at 6:50 AM |
 | ViewRay Unveils New Soft Tissue Visualization Technologies to Further Advance MR Image-Guided Radiotherapy
finance.yahoo.com - April 18 at 5:38 PM |
| Viewray (VRAY) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM |
| Trimedyne (TMED) versus Viewray (VRAY) Financial Contrast
www.americanbankingnews.com - April 10 at 9:14 PM |
| Viewray Inc (VRAY) Expected to Post Quarterly Sales of $15.50 Million
www.americanbankingnews.com - April 8 at 4:31 AM |
| -$0.22 Earnings Per Share Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - April 6 at 9:01 AM |
| Mizuho Reiterates "Buy" Rating for Viewray (VRAY)
www.americanbankingnews.com - April 5 at 12:39 PM |
| University Clinic Heidelberg Completes Installation and Commissioning of ViewRay's MRIdian MR Image-Guided ...
www.prnewswire.com - April 4 at 4:32 PM |
| University Clinic Heidelberg Completes Installation and Commissioning of ViewRay's MRIdian MR Image-Guided Radiotherapy Linac
finance.yahoo.com - April 4 at 4:32 PM |
| Technical Perspectives on Medical Equipment Stocks -- Smith & Nephew, Stryker, ViewRay, and Zimmer Biomet
www.prnewswire.com - April 2 at 8:54 AM |
| Viewray Inc (VRAY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 8:03 AM |
| Viewray (VRAY) PT Set at $13.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:35 PM |
| Viewray's (VRAY) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - March 29 at 10:16 PM |
| BidaskClub Lowers Viewray (VRAY) to Hold
www.americanbankingnews.com - March 29 at 3:00 PM |
| Viewray (VRAY) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 28 at 8:05 AM |
| RAD Technology Medical Systems Purchases Two ViewRay MRIdian Linac Systems
www.prnewswire.com - March 27 at 5:30 PM |
| ViewRay Surpasses 50th Order for MRIdian® System for Precision Cancer Treatment
finance.yahoo.com - March 27 at 5:30 PM |
| Brokers Issue Forecasts for Viewray Inc's FY2018 Earnings (VRAY)
www.americanbankingnews.com - March 22 at 10:40 AM |
| $13.80 Million in Sales Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - March 22 at 5:54 AM |
| VRAY: 2018 Could Be Pivotal For ViewRay
finance.yahoo.com - March 21 at 5:55 PM |
| Zacks Investment Research Weighs in on Viewray Inc's Q1 2018 Earnings (VRAY)
www.americanbankingnews.com - March 21 at 6:46 AM |
| -$0.23 EPS Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - March 20 at 9:00 AM |
| Stock Traders Purchase High Volume of Viewray Call Options (VRAY)
www.americanbankingnews.com - March 20 at 6:42 AM |
| Stock Traders Buy High Volume of Put Options on Viewray (VRAY)
www.americanbankingnews.com - March 20 at 6:40 AM |
| Viewray (VRAY) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 18 at 4:24 PM |
| Reviewing Viewray (VRAY) & Accuray (ARAY)
www.americanbankingnews.com - March 17 at 1:02 AM |
| Reviewing Boston Scientific (BSX) and Viewray (VRAY)
www.americanbankingnews.com - March 16 at 9:06 PM |
| Viewray Inc (VRAY) Insider Sells $569,589.51 in Stock
www.americanbankingnews.com - March 16 at 7:52 PM |
| Viewray Inc (VRAY) to Post FY2018 Earnings of ($0.64) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 16 at 10:02 AM |
| Nearly 200 Oncology Experts Gather to Discuss Advanced Applications of MR Image-Guided Radiotherapy
finance.yahoo.com - March 16 at 8:42 AM |
| ViewRay's MRIdian MR Image-Guided Radiotherapy Linac Receives Japanese Regulatory Approval (Shonin)
finance.yahoo.com - March 15 at 9:19 AM |
| Q1 2018 EPS Estimates for Viewray Inc Cut by B. Riley (VRAY)
www.americanbankingnews.com - March 15 at 6:28 AM |
| ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich
finance.yahoo.com - March 14 at 5:43 PM |
 | ViewRay Inc. (VRAY) PT Maintained at $12 at Mizuho Securities on 4Q Report; 'Not Concerned... 2018 Guidance Likely ... - StreetInsider.com
www.streetinsider.com - March 13 at 9:28 AM |
| ViewRay Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 5:44 PM |
| What Is ViewRay Inc’s (NASDAQ:VRAY) Share Price Doing?
finance.yahoo.com - March 12 at 5:44 PM |
| Viewray (VRAY) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS
www.americanbankingnews.com - March 12 at 9:20 AM |
| B. Riley Equities Analysts Raise Earnings Estimates for Viewray Inc (VRAY)
www.americanbankingnews.com - March 12 at 2:50 AM |
 | Pre-Market Earnings Report for March 12, 2018 : ACRS, VRAY, TNP, NERV, EGLT - Nasdaq
www.nasdaq.com - March 9 at 5:54 PM |
| Viewray Inc (VRAY) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 12:27 PM |
| ViewRay Announces Conference Call and Webcast of Fourth ... - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:31 AM |
| ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2017 Financial Results to be Held on March 12, 2018
finance.yahoo.com - March 6 at 5:32 PM |
| 947,306 Shares in Viewray Inc (VRAY) Acquired by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 3:35 PM |
| Analysts Anticipate Viewray Inc (VRAY) Will Announce Quarterly Sales of $20.09 Million
www.americanbankingnews.com - March 5 at 9:58 AM |
| Next Century Growth Investors LLC Has $5.49 Million Position in Viewray Inc (VRAY)
www.americanbankingnews.com - March 3 at 3:55 PM |
Viewray (NASDAQ:VRAY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Viewray (NASDAQ VRAY) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
